Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents

作者：Liang Zheng D; Long Yan; Tsai Wen Bin; Fu Siqing; Kurzrock Razelle; Gagea Iurascu Mihai; Zhang Fan; Chen Helen H W; Hennessy Bryan T; Mills Gordon B; Savaraj Niramol; Kuo Macus Tien^*

来源：Molecular Cancer Therapeutics, 2012, 11(11): 2483-2494.

DOI：10.1158/1535-7163.MCT-12-0580

Platinum-based antitumor agents are widely used in cancer chemotherapy. Drug resistance is a major obstacle to the successful use of these agents because once drug resistance develops, other effective treatment options are limited. Recently, we conducted a clinical trial using a copper-lowering agent to overcome platinum drug resistance in ovarian cancer patients and the preliminary results are encouraging. In supporting this clinical study, using three pairs of cisplatin (cDDP)-resistant cell lines and two ovarian cancer cell lines derived from patients who had failed in platinum-based chemotherapy, we showed that cDDP resistance associated with reduced expression of the high-affinity copper transporter (hCtr1), which is also a cDDP transporter, can be preferentially resensitized by copper-lowering agents because of enhanced hCtr1 expression, as compared with their drug-sensitive counterparts. Such a preferential induction of hCtr1 expression in cDDP-resistant variants by copper chelation can be explained by the mammalian copper homeostasis regulatory mechanism. Enhanced cell-killing efficacy by a copper-lowering agent was also observed in animal xenografts bearing cDDP-resistant cells. Finally, by analyzing a public gene expression dataset, we found that ovarian cancer patients with elevated levels of hCtr1 in their tumors, but not ATP7A and ATP7B, had more favorable outcomes after platinum drug treatment than those expressing low hCtr1 levels. This study reveals the mechanistic basis for using copper chelation to overcome cDDP resistance in clinical investigations. Mol Cancer Ther; 11(11); 2483-94.

• 出版日期2012-11